The value and distribution of high-density lipoprotein subclass in patients with acute coronary syndrome

Abstract

Background: High-density lipoprotein (HDL) enhances cholesterol efflux from the arterial wall and exhibits potent anti-inflammatory and anti-atherosclerosis (AS) properties. Whether raised HDL levels will clinically benefit patients with acute coronary syndrome (ACS) and the value at which these effects will be apparent, however, is debatable. This study examined the HDL subclass distribution profile in patients with ACS.

Methods: Plasma HDL subclasses were measured in 158 patients with established ACS and quantified by two-dimensional gel electrophoresis and immunoblotting. ACS diagnosis was based on symptoms of cardiac ischemia, electrocardiogram (ECG) abnormalities, speciality cardiac enzyme change along with presence of coronary heart disease (CHD) on coronary angiography.

Results: The small-sized preβ1-HDL, HDL3b, and HDL3a levels were significantly higher, and the large-sized HDL2a and HDL2b levels were significantly lower in patients with ACS than in those with stable angina pectoris (SAP) and in normal control subjects. Meanwhile, with an elevation in the low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG), body mass index (BMI), and blood pressure (BP), and the reduction in the high density lipoprotein cholesterol (HDL-C) levels, the HDL2b contents significantly decreased and the preβ1-HDL contents significantly increased in patients with ACS. The correlation analysis revealed that the apolipoprotein (apo)A-I levels were positively and significantly with all HDL subclasses contents; plasma total cholesterol (TC) and fasting plasma glucose (FPG) levels were inversely associated with HDL2a, and HDL2b. Moreover, the FPG levels were positively related to HDL3c, HDL3b, and HDL3a in ACS patients.

Conclusion: The HDL subclass distribution profile remodeling was noted in the patients with ACS. Plasma lipoprotein and FPG levels, BP, and BMI play an important role in the HDL subclass metabolism disorder for patients with ACS. The HDL subclass distribution phenotype might be useful as a novel biomarker to assist in the risk stratification of patients with ACS.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Characteristics of Major HDL Subclasses (Preβ1-HDL, and HDL2b) Distribution in ACS Patients According to Plasma LDL-C and HDL-C Concentrations.

Valued are expressed as means. The values in the denote the LDL-C/HDL-C ratio; N: number; *P<0.05, **P<0.01, ***P<0.001, compared with the HDL-C<1.03 mmol/L subgroup within the same LDL-C group. #P<0.05, ##P<0.01, ###P<0.001 compared with the same HDL-C subgroup within the LDL-C<3.34 mmol/L group.

Figure 2. Characteristics of Major HDL Subclasses (Preβ1-HDL, and HDL2b) Distribution in ACS patients according to SBP and DBP Levels.

In this chart, the red column stands for the contents of HDL2b and the yellow column stands for those of preβ1-HDL.

Figure 3. Characteristics of Major HDL Subclasses (Preβ1-HDL, and HDL2b) Distribution in ACS patients According to FPG and BMI.

In this chart, the blue column stands for the contents of HDL2b and the green column stands for those of preβ1-HDL.